Department of Nutrition Science, Purdue University, West Lafayette, IN, USA.
Adv Nutr. 2021 Mar 31;12(2):546-565. doi: 10.1093/advances/nmaa104.
Accumulating evidence indicates that the gut microbiota can promote or inhibit colonic inflammation and carcinogenesis. Promotion of beneficial gut bacteria is considered a promising strategy to alleviate colonic diseases including colitis and colorectal cancer. Interestingly, dietary polyphenols, which have been shown to attenuate colitis and inhibit colorectal cancer in animal models and some human studies, appear to reach relatively high concentrations in the large intestine and to interact with the gut microbial community. This review summarizes the modulatory effects of polyphenols on the gut microbiota in humans and animals under healthy and diseased conditions including colitis and colitis-associated colorectal cancer (CAC). Existing human and animal studies indicate that polyphenols and polyphenol-rich whole foods are capable of elevating butyrate producers and probiotics that alleviate colitis and inhibit CAC, such as Lactobacillus and Bifidobacterium. Studies in colitis and CAC models indicate that polyphenols decrease opportunistic pathogenic or proinflammatory microbes and counteract disease-induced dysbiosis. Consistently, polyphenols also change microbial functions, including increasing butyrate formation. Moreover, polyphenol metabolites produced by the gut microbiota appear to have anticancer and anti-inflammatory activities, protect gut barrier integrity, and mitigate inflammatory conditions in cells and animal models. Based on these results, we conclude that polyphenol-mediated alteration of microbial composition and functions, together with polyphenol metabolites produced by the gut microbiota, likely contribute to the protective effects of polyphenols on colitis and CAC. Future research is needed to validate the causal role of the polyphenol-gut microbiota interaction in polyphenols' anti-colitis and anti-CAC effects, and to further elucidate mechanisms underlying such interaction.
越来越多的证据表明,肠道微生物群可以促进或抑制结肠炎症和癌变。促进有益的肠道细菌被认为是一种有前途的策略,可以缓解包括结肠炎和结直肠癌在内的结肠疾病。有趣的是,膳食多酚在动物模型和一些人体研究中被证明可以减轻结肠炎并抑制结直肠癌,它们似乎在大肠中达到相对较高的浓度,并与肠道微生物群落相互作用。这篇综述总结了多酚在健康和疾病条件下(包括结肠炎和结肠炎相关的结直肠癌)对人和动物肠道微生物群的调节作用。现有的人体和动物研究表明,多酚和富含多酚的全食物能够提高丁酸产生菌和益生菌的水平,从而缓解结肠炎和抑制 CAC,如乳杆菌和双歧杆菌。在结肠炎和 CAC 模型中的研究表明,多酚可以减少机会性病原体或促炎微生物,并对抗疾病引起的微生物失调。一致地,多酚也改变了微生物的功能,包括增加丁酸的形成。此外,肠道微生物群产生的多酚代谢物似乎具有抗癌和抗炎活性,保护肠道屏障的完整性,并减轻细胞和动物模型中的炎症状态。基于这些结果,我们得出结论,多酚介导的微生物组成和功能的改变,以及肠道微生物群产生的多酚代谢物,可能有助于多酚对结肠炎和 CAC 的保护作用。需要进一步的研究来验证多酚-肠道微生物群相互作用在多酚抗结肠炎和抗 CAC 效应中的因果关系,并进一步阐明这种相互作用的机制。